Vimentin antibody (VIM)

Details for Product anti-VIM Antibody No. ABIN969453, Supplier: Log in to see
Antigen
  • vime
  • CTRCT30
  • cb28
  • vim
  • vim1
  • vim2
  • VIM
  • Vimentin
  • vimentin
  • Vimentin
  • vimentin-like
  • VIM
  • vim
  • vime
  • Vim
  • vim-a
  • LOC100522394
Alternatives
anti-Human Vimentin antibody for Blocking Antibody
Reactivity
Human
856
367
317
220
138
132
118
83
81
52
50
43
41
37
30
12
8
6
5
5
5
3
3
2
2
1
1
1
1
1
Host
Mouse
523
300
29
14
12
9
8
6
Clonality (Clone)
Monoclonal ()
Conjugate
This Vimentin antibody is un-conjugated
28
27
24
21
15
14
12
11
11
11
11
11
11
11
11
10
5
5
5
3
3
3
3
3
3
3
3
3
3
2
2
Application
Immunohistochemistry (IHC), ELISA, Western Blotting (WB)
678
292
288
270
240
227
219
114
84
40
15
14
13
10
8
8
5
3
3
3
1
1
1
1
1
Options
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Get this product for free

It's quick and easy to submit your validation proposal. I want to validate this product

Learn more

Available images

Immunogen Purified recombinant fragment of Vimentin expressed in E. Coli.
Clone 9E7E7
Isotype IgG1
Purification Ascites
Alternative Name Vimentin (VIM Antibody Abstract)
Background Vimentin is the major subunit protein of the intermediate filaments of mesenchymal cells. It is believed to be involved with the intracellular transport of proteins between the nucleus and plasma membrane. Vimentin has been implicated to be involved in the rate of steroid synthesis via its role as a storage network for steroidogenic cholesterol containing lipid droplets. Vimentin phosphorylation by a protein kinase causes the breakdown of intermediate filaments and activation of an ATP and myosin light chain dependent contractile event. This results in cytoskeletal changes that facilitate the interaction of the lipid droplets within mitochondria, and subsequent transport of cholesterol to the organelles leading to an increase in steroid synthesis. Immunohistochemical staining for Vimentin is characteristic of sarcomas (of neural, muscle and fibroblast origin) compared to carcinomas which are generally negative. Melanomas, lymphomas and vascular tumors may all stain for Vimentin. Vimentin antibodies are thus of value in the differential diagnosis of undifferentiated neoplasms and malignant tumors. They are generally used with a panel of other antibodies including those recognising cytokeratins, lymphoid markers, S100, desmin and neurofilaments.
Gene ID 7431
HGNC 7431
Research Area Lineage Markers, Cytoskeleton, Neural Stem Cell marker, Cell/Tissue Markers
Pathways TCR Signaling, Caspase Cascade in Apoptosis
Application Notes ELISA: 1:10000, WB: 1:500 - 1:2000, IHC: 1:200 - 1:1000
Restrictions For Research Use only
Format Liquid
Buffer Ascitic fluid containing 0.03 % sodium azide.
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage 4 °C,-20 °C
Storage Comment 4°C, -20°C for long term storage
Supplier Images
Immunohistochemistry (IHC) image for anti-Vimentin antibody (VIM) (ABIN969453) Figure 1: Immunohistochemical analysis of paraffin-embedded human lung carcinoma tiss...
Western Blotting (WB) image for anti-Vimentin antibody (VIM) (ABIN969453) Figure 2: Western blot analysis using Vimentin mouse mAb against truncated Vimentin r...
Product cited in: Vanzi: "Freedom at home: state constitutions and Medicaid funding for abortions." in: New Mexico law review, Vol. 26, Issue 3, pp. 433-54, 2005 (PubMed).

Background publications Seshadri, Raymond, Leong, Horsfall, McCaul: "Vimentin expression is not associated with poor prognosis in breast cancer." in: International journal of cancer. Journal international du cancer, Vol. 67, Issue 3, pp. 353-6, 1996 (PubMed).

Essa, el Tatawi, Hamdi, Arafa: "Vimentin expression in different types of breast carcinoma immunohistochemical study." in: Journal of the Egyptian Society of Parasitology, Vol. 26, Issue 2, pp. 433-42, 1996 (PubMed).

Chu, Seftor, Romer, Hendrix: "Experimental coexpression of vimentin and keratin intermediate filaments in human melanoma cells augments motility." in: The American journal of pathology, Vol. 148, Issue 1, pp. 63-9, 1996 (PubMed).